Key CAR T-Cell Therapy Market Players:
- Novartis
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead/Kite Pharma
- Bristol Myers Squibb
- Janssen (Johnson & Johnson)
- Legend Biotech
- CARsgen
- Bluebird Bio
- Autolus Therapeutics
- Celyad Oncology
- Poseida Therapeutics
- JW Therapeutics
- Gracell Biotechnologies
- Immuneel Therapeutics
- LG Chem
- Cartesian Therapeutics
- Mustang Bio
- CellVec
- Kazia Therapeutics
- Takeda
- Daiichi Sankyo
The market commercial leadership is followed by the clinical and financial achievements of market leaders such as Novartis, Gilead, and Bristol Myers Squibb. Their commercialization strategy for FDA/EMA-approved treatments, effective pricing structure, and product development are collectively driving this market toward healthy competitiveness. Additionally, innovators like Poseida Therapeutics are leading the way in allogeneic off-the-shelf platforms that reduce vein-to-vein time from weeks to days, which is extending the industry's reach, even to underserved areas.
Below is the list of some prominent players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
CAR T-cell therapy market size was valued at USD 6 billion in 2025.
CAR T-cell therapy market size was valued at USD 6 billion in 2025 and is projected to reach USD 45.6 billion by the end of 2035, rising at a CAGR of 22.5% during the forecast period, i.e., 2026-2035.
The major players in the market are Novartis, Gilead/Kite Pharma, Bristol Myers Squibb, Janssen (Johnson & Johnson), Legend Biotech, CARsgen, Bluebird Bio, Autolus Therapeutics, Celyad Oncology, Poseida Therapeutics, JW Therapeutics, Gracell Biotechnologies, Immuneel Therapeutics, LG Chem, Cartesian Therapeutics, Mustang Bio, CellVec, Kazia Therapeutics, Takeda, Daiichi Sankyo.
Hospitals dominate the end use segment and are set to hold a share value of 87.6% in 2035.
North America is expected to dominate the global market with a share of 48.2% by the end of 2035.
